AU2009241355B2 - Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc - Google Patents

Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc Download PDF

Info

Publication number
AU2009241355B2
AU2009241355B2 AU2009241355A AU2009241355A AU2009241355B2 AU 2009241355 B2 AU2009241355 B2 AU 2009241355B2 AU 2009241355 A AU2009241355 A AU 2009241355A AU 2009241355 A AU2009241355 A AU 2009241355A AU 2009241355 B2 AU2009241355 B2 AU 2009241355B2
Authority
AU
Australia
Prior art keywords
administration
period
treatment
female
cdb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009241355A
Other languages
English (en)
Other versions
AU2009241355A1 (en
Inventor
Joseph S. Podolski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Allergan Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Pharmaceuticals International Ltd filed Critical Allergan Pharmaceuticals International Ltd
Publication of AU2009241355A1 publication Critical patent/AU2009241355A1/en
Application granted granted Critical
Publication of AU2009241355B2 publication Critical patent/AU2009241355B2/en
Assigned to Allergan pharmaceuticals International Ltd. reassignment Allergan pharmaceuticals International Ltd. Request for Assignment Assignors: REPROS THERAPEUTICS INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AU2009241355A 2008-04-28 2009-04-27 Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc Ceased AU2009241355B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28
US61/048,472 2008-04-28
PCT/US2009/041826 WO2009134718A1 (en) 2008-04-28 2009-04-27 Pregesteron antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Publications (2)

Publication Number Publication Date
AU2009241355A1 AU2009241355A1 (en) 2009-11-05
AU2009241355B2 true AU2009241355B2 (en) 2013-11-14

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009241355A Ceased AU2009241355B2 (en) 2008-04-28 2009-04-27 Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Country Status (24)

Country Link
US (2) US8426394B2 (enExample)
EP (1) EP2293797B1 (enExample)
JP (1) JP5791499B2 (enExample)
KR (2) KR20130059442A (enExample)
CN (2) CN105616427A (enExample)
AR (1) AR071516A1 (enExample)
AU (1) AU2009241355B2 (enExample)
BR (1) BRPI0911563A2 (enExample)
CA (1) CA2722753C (enExample)
CL (1) CL2009001010A1 (enExample)
DK (1) DK2293797T3 (enExample)
EA (3) EA201990835A3 (enExample)
ES (1) ES2561810T3 (enExample)
IL (1) IL208844A0 (enExample)
ME (1) ME01123B (enExample)
MX (1) MX2010011272A (enExample)
MY (1) MY161059A (enExample)
NI (1) NI201000183A (enExample)
NZ (1) NZ589533A (enExample)
SG (1) SG10201408483QA (enExample)
TW (1) TWI477276B (enExample)
UA (1) UA102849C2 (enExample)
WO (1) WO2009134718A1 (enExample)
ZA (1) ZA201007529B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014029131B1 (pt) * 2012-05-31 2021-03-09 Allergan Pharmaceuticals International Limited cápsula de mucoadesivo
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
HK1211852A1 (en) 2012-11-02 2016-06-03 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451780B1 (en) * 1995-02-02 2002-09-17 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
WO2006136462A1 (en) * 2005-06-24 2006-12-28 Bayer Schering Pharma Aktiengesellschaft Benzofuranone derivatives as nonsteroidal progesterone receptor modulators
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding
AU2007327707B2 (en) * 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
HUT74465A (en) * 1993-11-16 1996-12-30 Schering Ag Pharmaceutical composition which useable for treatment of uterine contractility disorders containing a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
JP4260886B2 (ja) * 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
ES2546291T3 (es) * 2000-03-17 2015-09-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 17-Alfa-sustituida, 11-beta-sustituida-4-arilo y 21-sustituida 19-norpregnadienodionas como agentes antiprogestacionales
IN191020B (enExample) * 2000-03-28 2003-09-13 Dabur Res Foundation
WO2001074684A2 (en) 2000-04-03 2001-10-11 Astenjohnson, Inc. Pre-crimped tie components
CN1512886A (zh) * 2000-10-18 2004-07-14 ���ֹɷݹ�˾ 抗孕激素预防和治疗激素依赖性疾病的用途
CA2777199A1 (en) 2001-07-09 2003-01-23 Repros Therapeutics Inc. Methods and materials for the treatment of testosterone deficiency in men
EP1620060B1 (en) 2003-04-29 2010-03-24 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
WO2006010097A2 (en) * 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
MX2009007313A (es) * 2007-01-17 2009-07-15 Repros Therapeutics Inc Metodos para estabilidad mejorada de derivados de esteroides.
EP2144601A4 (en) 2007-04-05 2012-10-10 Univ Kansas RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2482914A1 (en) 2009-09-29 2012-08-08 Koninklijke Philips Electronics N.V. Intrauterine electronic capsule for administering a substance

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451780B1 (en) * 1995-02-02 2002-09-17 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
WO2006136462A1 (en) * 2005-06-24 2006-12-28 Bayer Schering Pharma Aktiengesellschaft Benzofuranone derivatives as nonsteroidal progesterone receptor modulators
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
AU2007327707B2 (en) * 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation
WO2008129396A2 (en) * 2007-04-20 2008-10-30 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATTARDI BJ, et al. Molecular and Cellular Endrocrinology, (2002), Vol 188 pp 111-123. *
LEO JCL. et al. 'The activities of progesterone receptor isoform A and B are differentially modulated by their ligands in a gene selective manner,' Int J. Cancer, (2008) Vol 122, pp 230-243. *
MEALY NE et al. 'CDB-4124,' Drugs of the Future, (2004) Vol 29 No 11 pp 1133. *

Also Published As

Publication number Publication date
MY161059A (en) 2017-04-14
US8426394B2 (en) 2013-04-23
BRPI0911563A2 (pt) 2016-07-12
EP2293797B1 (en) 2015-11-11
CN102014923A (zh) 2011-04-13
TW200950786A (en) 2009-12-16
CA2722753C (en) 2018-07-03
CA2722753A1 (en) 2009-11-05
MX2010011272A (es) 2010-12-21
EA032646B1 (ru) 2019-06-28
EA201990835A3 (ru) 2019-12-30
DK2293797T3 (en) 2016-01-11
EA201990835A2 (ru) 2019-08-30
AR071516A1 (es) 2010-06-23
IL208844A0 (en) 2011-01-31
ES2561810T3 (es) 2016-03-01
US20110046098A1 (en) 2011-02-24
WO2009134718A1 (en) 2009-11-05
JP2011518845A (ja) 2011-06-30
ME01123B (me) 2013-03-20
AU2009241355A1 (en) 2009-11-05
US8735381B2 (en) 2014-05-27
EP2293797A1 (en) 2011-03-16
US20130289008A1 (en) 2013-10-31
UA102849C2 (ru) 2013-08-27
ZA201007529B (en) 2011-07-27
KR20130059442A (ko) 2013-06-05
KR20110014162A (ko) 2011-02-10
JP5791499B2 (ja) 2015-10-07
SG10201408483QA (en) 2015-02-27
CN105616427A (zh) 2016-06-01
NZ589533A (en) 2012-06-29
EA201071249A1 (ru) 2011-08-30
CL2009001010A1 (es) 2009-06-19
NI201000183A (es) 2012-06-06
WO2009134718A8 (en) 2010-09-23
TWI477276B (zh) 2015-03-21
EA201401347A1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
AU2009241355B2 (en) Progesterone antagonists such as CDB-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
AU2007327707B2 (en) Compositions and methods for suppressing endometrial proliferation
US20090118253A1 (en) Compositions and methods for treating dysfunctional uterine bleeding
CN101528764A (zh) 用于抑制子宫内膜增生的组合物和方法
HK1135111A (en) Compositions and methods for suppressing endometrial proliferation
HK1225606A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer
HK1225606A1 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer
HK1155085A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD.

Free format text: FORMER OWNER(S): REPROS THERAPEUTICS INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired